Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
TARA
TARA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TARA News
JP Morgan Initiates Protara with Overweight Rating
6d ago
seekingalpha
Latest Ratings and Price Targets on Wall Street
6d ago
CNBC
Protara Therapeutics Reports Interim Data for TARA-002 in Bladder Cancer Trial
Feb 24 2026
seekingalpha
Protara Therapeutics Updates TARA-002 Trial Results
Feb 24 2026
Benzinga
Keysight Technologies Quarterly Earnings Beat Estimates
Feb 24 2026
Benzinga
Protara's Bladder Cancer Trial Shows Strong Efficacy
Feb 24 2026
stocktwits
Protara Updates on TARA-002 Clinical Trial Results
Feb 23 2026
Newsfilter
ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis
Jan 09 2026
NASDAQ.COM
Protara Doses First Patient in Pivotal THRIVE-3 Trial for IV Choline Chloride
Jan 07 2026
NASDAQ.COM
Protara Therapeutics Receives FDA Breakthrough and Fast Track Designations for TARA-002
Jan 05 2026
Globenewswire
Protara Closes $75 Million Public Offering of 13 Million Shares
Dec 08 2025
Globenewswire
Protara Therapeutics Closes $75 Million Public Offering of 13 Million Shares
Dec 08 2025
Newsfilter
Protara Secures $75 Million Funding to Support TARA-002 and Expand Pipeline Development
Dec 05 2025
NASDAQ.COM
Protara Therapeutics Stock Drops 16% Following $75 Million Public Offering
Dec 05 2025
NASDAQ.COM
Ulta Beauty Stock Rises Approximately 6%; Check Out 20 Stocks Making Moves in Premarket Trading
Dec 05 2025
Benzinga
Protara Prices 13.04M Shares at $5.75, Raising $75M for Clinical Development
Dec 05 2025
Globenewswire
Show More News
